Home › Vertex Pharmaceuticals Incorporated (VRTX) Earns Outperform Rating from Leerink Swann
 

Keywords :   


Vertex Pharmaceuticals Incorporated (VRTX) Earns Outperform Rating from Leerink Swann

2016-04-10 19:10:39| Biotech - Topix.net

A number of other research firms also recently weighed in on VRTX. Piper Jaffray reaffirmed an overweight rating and set a $180.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 5th.

Tags: rating incorporated pharmaceuticals earns

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
16.05Firms leaving UK 'not a crisis' says stock market boss
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
More »